Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
NASDAQ:ARVN

Arvinas Q3 2026 Earnings Date & Estimates

Arvinas logo
$7.64 +0.13 (+1.73%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$7.76 +0.12 (+1.57%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arvinas is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Arvinas in Q3 2026

Arvinas is expected to post earnings of -$0.8672 per share on revenue of $16.82 million. In the same quarter a year earlier Arvinas reported -$0.48 per share on revenue of $41.90 million. Arvinas last reported on August 4, 2026, posting $2.58 per share and beating the -$0.3741 consensus estimate. Arvinas has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.8672
Expected Revenue
$16.82 million
Prior-Year EPS
-$0.48
Prior-Year Revenue
$41.90 million
Expected Revenue Growth
-59.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$2.58 (Beat by +$2.9541)
Last Quarter Revenue
$249.70 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Arvinas Q3 2026 Earnings FAQ

Arvinas (NASDAQ:ARVN) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens.

Arvinas' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Arvinas to post earnings of -$0.8672 per share for Q3 2026.

The consensus revenue estimate for Arvinas is $16.82 million for Q3 2026.

Arvinas Earnings Headlines

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Arvinas Holding Company (ARVN) and Ovid Therapeutics (OVID)
October 9 at 2:45 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BHC/pressreleases/5341770/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bausch-health-companies-bhc-arvinas-holding-company-arvn-and-ovid-therapeutics-ovid/
Arvinas, Inc. (NASDAQ:ARVN) Stock Rated "Hold" by Wall Street Analysts
October 8 at 2:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098054
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
October 11 at 1:00 AM  |  Porter & Company (Ad)
Arvinas' ARV-102 Shows Biomarker Changes In Parkinson's Phase 1 Trial
October 7, 2026  |  rttnews.comhttps://www.rttnews.com/3697174/arvinas-arv-102-shows-biomarker-changes-in-parkinson-s-phase-1-trial.aspx
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
October 7, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/arvinas-shares-novel-oculomotor-and-biomarker-data-from-phase-1-clinical-trial-of-arv-102-in-patients-with-parkinson-s-disease-1036604475
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376329/0/en/arvinas-shares-novel-oculomotor-and-biomarker-data-from-phase-1-clinical-trial-of-arv-102-in-patients-with-parkinson-s-disease.html
See More Arvinas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arvinas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arvinas and other key companies, straight to your email.

About Arvinas

Arvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary PROTAC targeted protein degradation platform to design small-molecule therapies intended to direct unwanted proteins to the cell’s natural disposal system.

Arvinas’ programs have primarily focused on oncology. Its lead investigational program, vepdegestrant (ARV-471), is an oral estrogen receptor degrader being developed for patients with estrogen receptor-positive, HER2-negative breast cancer. The program is being advanced in collaboration with Pfizer. Arvinas has also developed additional targeted protein degraders aimed at cancer-related targets, including androgen receptor and BCL6, and has explored applications of the technology in neurological diseases.

Founded in 2013 and headquartered in New Haven, Connecticut, Arvinas grew out of research associated with Yale University and the work of scientist Craig Crews, who helped pioneer the PROTAC approach. The company conducts research and development activities in the United States and works with strategic partners to advance selected programs. Arvinas is led by President and Chief Executive Officer John Houston.

View Arvinas Profile
Earnings Tools